

COMPUGEN: FROM CODE TO CURE®

○ **Investment Rational**

Compugen is a clinical-stage drug-discovery company utilizing its broadly applicable, predictive computational discovery platforms to identify novel biological pathways and drug targets and develop therapeutics in the field of cancer immunotherapy. Our innovative pipeline consists of multiple programs, four of which are at clinical stage development, and is complemented and validated by existing collaborations with Bristol-Myers Squibb, AstraZeneca and Bayer.

○ **Business Strategy**

Compugen seeks to leverage its existing and constantly evolving pipeline of internally discovered product candidates to enter various forms of collaborations with pharmaceutical or biotechnology partners, with the aim to advance our early- and clinical-stage programs and bring transformational medicines that generate value for patients

○ **Core Technology**

Compugen's unique value proposition is based on its broad and innovative computational-discovery capabilities, which are complemented by extensive research, drug-discovery, and clinical expertise. These are validated by collaborations with prominent industry and academic leaders in the IO space and have conjured an innovative immuno-oncology portfolio with three internally discovered new drug targets serving as the basis for our clinical assets.

○ **Product Profile/Pipeline**

Our pipeline consists of computationally discovered early and clinical stage programs targeting biological pathways and drug-targets aiming to address the significant unmet need of refractory/relapsing cancer patient population. Our lead wholly owned assets: COM701 and COM902, are well-tolerated in monotherapy and in combination, and demonstrated initial signs of anti-tumor activity and immune activation in heavily pre-treated cancer patients.

○ **What's Next?**

Compugen is currently conducting multiple Phase 1 trials in various indications and combinations. Our biomarker-informed trials in selected indications have recently started and we are looking forward to sharing clinical results as the data matures. In parallel, we are continuously investing in our internal capabilities, expanding our pipeline with novel targets, and seeking additional business opportunities.